Frailty and COVID-19 mRNA Vaccine Antibody Response in the COVID-19 Community Research Partnership

作者：Charles Semelka, Michael DeWitt, Kathryn E. Callahan, David M. Herrington, Martha A. Alexander‐Miller, Joshua Yukich, Iqra Munawar, Lewis McCurdy, Michael Gibbs, William S. Weintraub, John W. Sanders · 发表于：The Journals of Gerontology Series A · 年份：2022 · DOI：10.1093/gerona/glac095 · 被引用次数：34 · 研究领域：Frailty in Older Adults、SARS-CoV-2 and COVID-19 Research、Immune responses and vaccinations

BACKGROUND: COVID-19 has disproportionately affected older adults. Frailty has been associated with impaired vaccine response in other vaccine types, but the impact of frailty on mRNA vaccine response is undefined. METHODS: Observational study of adults aged 55 and older from 1 U.S. health care system between January 22, 2021 and September 16, 2021 with self-reported Moderna or Pfizer COVID-19 mRNA vaccine and an electronic frailty index (eFI) score from their medical record (n = 1 677). Participants' frailty status was compared with positive antibody detection (seroconversion) following full vaccination and subsequent loss of positive antibody detection (seroreversion) using logistic regression models. RESULTS: Of 1 677 older adults with median (interquartile range) age, 67 (62 and 72) years, and frailty status (nonfrail: 879 [52%], prefrail: 678 [40%], and frail: 120 [7.2%]), seroconversion was not detected in 23 (1.4%) over 60 days following full vaccination. Frail individuals were less likely to seroconvert than nonfrail individuals, adjusted odds ratio (OR) 3.75, 95% confidence interval (CI; 1.04, 13.5). Seroreversion was detected in 50/1 631 individuals (3.1%) over 6 months of median follow-up antibody testing. Frail individuals were more likely to serorevert than nonfrail individuals, adjusted OR 3.02, 95% CI (1.17, 7.33). CONCLUSION: Overall antibody response to COVID-19 mRNA vaccination was high across age and frailty categories. While antibody detection is an incomp...